TTI-101 Phase 2 Multicenter Trial for IPF: Safety, Tolerability, and Efficacy

This is an image of liquid being dropped into a test tube

Study Status


Enrollment Period


Eligibility Criteria


Accepts Healthy Volunteers
No

Contact Information


Sandy Ditta
504‐988‐4040

Select a tab above for more information.

 

Who Qualifies for this Study?

Not specified

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis

Study Overview

Conditions / Diseases


Idiopathic Pulmonary Fibrosis

Department / Organizations


Pulmonary, Critical Care & Environmental Medicine

Principal Investigator


Joseph Lasky, M.D.

ClinicalTrials.gov


Join a Clinical Trial Today

Help advance medicine and make a difference.

Frequently Asked Questions


We understand that deciding to join a clinical trial is a personal choice—and often one that comes with a lot of questions. Whether you're curious about how trials work, wondering about safety, or just want to know what to expect, you're in the right place.

What is a clinical trial?

Why should I consider participating?

Is it safe?

Will I be paid?

Can I leave a study at any time?

What happens if I have side effects?

Will my personal information be kept private?

Do I need health insurance to participate?